Back to Journals » HIV/AIDS - Research and Palliative Care » Volume 4

Review

Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment

       

Authors Pefura Yone EW, Kengne 

Received 2 October 2012

Accepted for publication 16 November 2012

Published 5 December 2012 Volume 2012:4 Pages 181—184

DOI https://doi.org/10.2147/HIV.S24432

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Download Article [PDF] 


Eric W Pefura Yone,1,2 André P Kengne3

1Department of Internal Medicine and Subspecialties, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Cameroon; 2Approved Centre for HIV Treatment and Pneumology Service, Yaounde Jamot Hospital, Cameroon; 3South African Medical Research Council and University of Cape Town, Cape Town, South Africa

Abstract: An extended-release formulation of nevirapine (NVP-XR) has been developed with the aim of simplifying antiretroviral treatment regimens and improving patients’ adherence with a single daily intake. The VERxVE and TRANxITION clinical trials have demonstrated the noninferiority of NVP-XR compared with nevirapine immediate-release (NVP-IR) on viral load after 24 and 48 months of treatment. The tolerance profiles of NVP-XR and NVP-IR are similar. Simplifying the treatment dosage for NVP would likely improve adherence to antiretroviral treatments.

Keywords: nevirapine extended release, HIV infection, antiretroviral therapy, efficacy, safety

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]